Jounce Therapeutics to Present at Upcoming Investor Conferences in September
August 30, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Names Hugh Cole as Chief Business Officer and Head of Corporate Development
August 15, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2017 Financial Results
August 09, 2017 06:30 ET
|
Jounce Therapeutics, Inc.
- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in...
Jounce Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9, 2017
August 02, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled...
Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting
June 05, 2017 09:00 ET
|
Jounce Therapeutics, Inc.
-- ICOS Agonist Antibody Well Tolerated Alone and as Combination Immunotherapy -- -- Phase 2 Monotherapy Cohorts Are Currently Enrolling Using ICOS Biomarker Patient Enrichment -- CAMBRIDGE,...
Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
May 17, 2017 17:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2017 Financial Results
May 09, 2017 08:00 ET
|
Jounce Therapeutics, Inc.
- Completed upsized initial public offering raising $117.1 million in gross proceeds -- Presented preclinical data supporting ongoing Phase 1/2 ICONIC study -- Initiated Phase 2 portion of ICONIC...
Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
April 20, 2017 16:01 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
March 31, 2017 16:01 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at AACR Annual Meeting on JTX-2011 Cancer Immunotherapy Program
March 22, 2017 16:01 ET
|
Jounce Therapeutics, Inc.
-- Invited oral presentation on JTX-2011 preclinical data -- -- Poster presentation on single agent and combination trial design -- CAMBRIDGE, Mass., March 22, 2017 (GLOBE NEWSWIRE) -- Jounce...